Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia

[Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia]

Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection

Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel

[Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles]

O033/#702 Pten and Molecular Classification As Prognostic Factors to Predict Fertility Preserving Treatment Outcomes in Patients with Endometrial Cancer and Endometrial Atypical Hyperplasia

Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer

Characteristics of Molecular Classification in 52 Endometrial Cancer and Atypical Hyperplasia Patients Receiving Fertility-Sparing Treatment

Use of Clinicopathological Factors to Predict Prognosis of Fertility-Sparing Treatment for Endometrial Endometrioid Carcinoma and Atypical Hyperplasia

Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management

Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups

Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours

Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response

Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components

Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience

Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups

Molecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel